Capital Group Investment Management PTE. LTD. Boosts Stock Holdings in Amgen Inc. $AMGN

Capital Group Investment Management PTE. LTD. increased its stake in Amgen Inc. (NASDAQ:AMGN) by 93.4% during the 3rd quarter, Holdings Channel reports. The fund owned 11,732 shares of the medical research company’s stock after purchasing an additional 5,666 shares during the quarter. Capital Group Investment Management PTE. LTD.’s holdings in Amgen were worth $3,311,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of AMGN. Evelyn Partners Investment Management LLP purchased a new stake in Amgen during the 2nd quarter worth about $32,000. Howard Hughes Medical Institute acquired a new stake in Amgen in the 2nd quarter valued at about $32,000. Cloud Capital Management LLC purchased a new position in shares of Amgen in the 3rd quarter valued at about $34,000. AXS Investments LLC purchased a new position in shares of Amgen in the 3rd quarter valued at about $42,000. Finally, Winnow Wealth LLC acquired a new position in shares of Amgen during the third quarter worth about $47,000. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on AMGN. Daiwa Securities Group upped their target price on shares of Amgen from $370.00 to $410.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 10th. Freedom Capital cut shares of Amgen from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 12th. Piper Sandler raised their price objective on shares of Amgen from $381.00 to $432.00 and gave the company an “overweight” rating in a report on Wednesday, February 18th. Royal Bank Of Canada boosted their target price on shares of Amgen from $335.00 to $360.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 4th. Finally, Wells Fargo & Company raised their price target on Amgen from $325.00 to $375.00 and gave the company an “equal weight” rating in a research note on Thursday, February 19th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, twelve have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $354.17.

Amgen Trading Up 2.0%

NASDAQ AMGN opened at $376.97 on Tuesday. The firm’s fifty day moving average price is $354.21 and its 200 day moving average price is $323.38. Amgen Inc. has a 12 month low of $261.43 and a 12 month high of $391.29. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90. The company has a market capitalization of $203.21 billion, a price-to-earnings ratio of 26.49, a price-to-earnings-growth ratio of 3.67 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. During the same quarter in the prior year, the firm posted $5.31 earnings per share. Amgen’s revenue for the quarter was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, sell-side analysts expect that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be paid a $2.52 dividend. The ex-dividend date is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a yield of 2.7%. Amgen’s payout ratio is currently 70.84%.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.